GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (FRA:ONYN) » Definitions » E10

Oncolytics Biotech (FRA:ONYN) E10 : €0.00 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Oncolytics Biotech E10?

Note: As E10 is a main component used to calculate Shiller PE Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation sectione below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Oncolytics Biotech's adjusted earnings per share data for the three months ended in Mar. 2024 was €0.000. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.00 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was 18.10% per year. During the past 5 years, the average E10 Growth Rate was 15.60% per year. During the past 10 years, the average E10 Growth Rate was 7.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Oncolytics Biotech was 18.10% per year. The lowest was -57.10% per year. And the median was -2.55% per year.

As of today (2024-05-19), Oncolytics Biotech's current stock price is €1.61. Oncolytics Biotech's E10 for the quarter that ended in Mar. 2024 was €0.00. Oncolytics Biotech's Shiller PE Ratio of today is .


Oncolytics Biotech E10 Historical Data

The historical data trend for Oncolytics Biotech's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech E10 Chart

Oncolytics Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.01 -1.41 - - -

Oncolytics Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oncolytics Biotech's E10

For the Biotechnology subindustry, Oncolytics Biotech's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncolytics Biotech's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's Shiller PE Ratio falls into.



Oncolytics Biotech E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oncolytics Biotech's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/126.2576*126.2576
=0.000

Current CPI (Mar. 2024) = 126.2576.

Oncolytics Biotech Quarterly Data

per share eps CPI Adj_EPS
201406 -0.323 99.473 -0.410
201409 -0.335 99.394 -0.426
201412 -0.267 98.367 -0.343
201503 -0.278 99.789 -0.352
201506 -0.205 100.500 -0.258
201509 -0.128 100.421 -0.161
201512 -0.191 99.947 -0.241
201603 -0.194 101.054 -0.242
201606 -0.131 102.002 -0.162
201609 -0.194 101.765 -0.241
201612 -0.313 101.449 -0.390
201703 -0.199 102.634 -0.245
201706 -0.214 103.029 -0.262
201709 -0.137 103.345 -0.167
201712 -0.212 103.345 -0.259
201803 -0.194 105.004 -0.233
201806 -0.176 105.557 -0.211
201809 -0.132 105.636 -0.158
201812 -0.183 105.399 -0.219
201903 -0.179 106.979 -0.211
201906 -0.173 107.690 -0.203
201909 -0.110 107.611 -0.129
201912 -0.567 107.769 -0.664
202003 -0.026 107.927 -0.030
202006 -0.111 108.401 -0.129
202009 -0.103 108.164 -0.120
202012 -0.141 108.559 -0.164
202103 -0.087 110.298 -0.100
202106 -0.088 111.720 -0.099
202109 0.000 112.905 0.000
202112 0.000 113.774 0.000
202203 0.000 117.646 0.000
202206 0.000 120.806 0.000
202209 0.000 120.648 0.000
202212 0.000 120.964 0.000
202303 0.000 122.702 0.000
202306 0.000 124.203 0.000
202309 0.000 125.230 0.000
202312 0.000 125.072 0.000
202403 0.000 126.258 0.000

Add all the adjusted EPS together and divide 10 will get our e10.


Oncolytics Biotech  (FRA:ONYN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Oncolytics Biotech E10 Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncolytics Biotech (FRA:ONYN) Business Description

Traded in Other Exchanges
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.

Oncolytics Biotech (FRA:ONYN) Headlines

No Headlines